Ad
BSTG Quote Trading Chart Biostage
home / stock / bstg / bstg quote
Quote | Biostage (OTCMKTS:BSTG)
| Last: | $4.03 |
|---|---|
| Change Percent: | -2.31% |
| Open: | $4.0925 |
| Close: | $4.03 |
| High: | $4.14 |
| Low: | $4 |
| Volume: | 4,533 |
| Last Trade Date Time: | 07/19/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
BSTG Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $4.03 | $4.0925 | $4.03 | $4.14 | $4 | 4,533 | 07-19-2023 |
| $4 | $4 | $4 | $4.44 | $4 | 4,715 | 07-18-2023 |
| $3.87 | $3.7162 | $3.87 | $3.87 | $3.65 | 1,775 | 07-17-2023 |
| $3.9 | $3.9 | $3.9 | $3.98 | $3.9 | 5,450 | 07-14-2023 |
| $3.9 | $4.115 | $3.9 | $4.115 | $3.9 | 1,750 | 07-12-2023 |
| $3.99 | $0 | $3.99 | $0 | $0 | 45 | 07-11-2023 |
| $3.99 | $0 | $3.99 | $0 | $0 | 7 | 07-10-2023 |
| $3.99 | $3.99 | $3.99 | $3.99 | $3.99 | 100 | 07-07-2023 |
| $4 | $4 | $4 | $4 | $4 | 200 | 07-06-2023 |
| $3.97 | $0 | $3.97 | $0 | $0 | 1 | 07-05-2023 |
| $3.97 | $3.97 | $3.65 | $3.97 | $3.97 | 200 | 07-04-2023 |
| $3.97 | $3.97 | $3.97 | $3.97 | $3.97 | 200 | 07-03-2023 |
| $3.65 | $3.71 | $3.65 | $3.71 | $3.65 | 762 | 06-30-2023 |
| $3.7865 | $3.7829 | $3.7865 | $3.7865 | $3.76 | 425 | 06-28-2023 |
| $3.76 | $3.89 | $3.76 | $3.89 | $3.76 | 624 | 06-27-2023 |
| $3.81 | $4.025 | $3.81 | $4.025 | $3.76 | 2,673 | 06-23-2023 |
| $4 | $4.3426 | $4 | $4.3494 | $4 | 5,400 | 06-22-2023 |
| $4.4 | $4.51 | $4.4 | $4.528 | $4.33 | 2,676 | 06-21-2023 |
| $4.52 | $4.57 | $4.52 | $4.57 | $4.52 | 1,523 | 06-20-2023 |
| $4.6 | $4.7 | $4.6 | $4.7 | $4.6 | 410 | 06-19-2023 |
News, Short Squeeze, Breakout and More Instantly...
Biostage Company Name:
BSTG Stock Symbol:
OTCMKTS Market:
-2.31% G/L:
$4.03 Last:
4,533 Volume:
$4.0925 Open:
$4.03 Close:
Biostage Website:
Ad
-
Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organ...
-
Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs in...
-
Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organ...
Important Investor News Alert (NASDAQ: CVKD)
-
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per ev...